Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.


A poor prognosis in chronic lymphocytic leukemia (CLL) is associated particularly with the presence of del(17p) aff ecting tumor suppressor gene TP53 . Th is deletion is in almost all cases of progressive leukemia accompanied by a mutation in the other TP53 allele, and in a smaller proportion of patients the TP53 mutation occurs also independently of del… (More)
DOI: 10.3109/10428194.2012.658794


2 Figures and Tables

Slides referencing similar topics